Long title
A phase II, multicenter study to determine the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma
Date receipt dossier
EU record number
bb2121-MM-001
EudraCT number
2017-002245-29
Company / Sponsor
Celgene
Phase
II
Treated organism
Humans
Indication category
Cancer therapy
Disease
relapsed and refractory multiple myeloma
Therapeutic approach
Immunotherapy
Genetic modification
BCMA02 (human B cell maturation antigen)-CAR
Method of transfer of nucleic acid of interest
Lentiviral vectors
Administered biological material
Autologous T-cells transduced with lentiviral vectors expressing BCMA02 (human B cell maturation antigen) CAR
Route of administration
Intravenous
Locations in Belgium
UZ Leuven
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
bb2121